These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

786 related items for PubMed ID: 25267953

  • 1. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A, Elisei W, Principi M, Inchingolo CD, Nenna R, Picchio M, Giorgio F, Ierardi E, Brandimarte G.
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [Abstract] [Full Text] [Related]

  • 2. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S, Gionchetti P, Rizzello F, Calabrese C, Campieri M.
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [Abstract] [Full Text] [Related]

  • 3. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E, Giorgio F, Zotti M, Rosania R, Principi M, Marangi S, Della Valle N, De Francesco V, Di Leo A, Ingrosso M, Panella C.
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G, Brandimarte G.
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [Abstract] [Full Text] [Related]

  • 5. Expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor α in resected acute colonic diverticulitis.
    Tursi A, Elisei W, Giorgetti GM, Inchingolo CD, Nenna R, Picchio M, Giorgio F, Ierardi E, Brandimarte G.
    Colorectal Dis; 2014 Mar; 16(3):O98-103. PubMed ID: 24283919
    [Abstract] [Full Text] [Related]

  • 6. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF, Planell N, Kajekar R, Lozano JJ, Ordás I, Dotti I, Esteller M, Masamunt MC, Parmar H, Ricart E, Panés J, Salas A.
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [Abstract] [Full Text] [Related]

  • 7. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [Abstract] [Full Text] [Related]

  • 8. Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study.
    Tursi A, Elisei W, Brandimarte G, Giorgetti GM, Inchingolo CD, Nenna R, Picchio M, Giorgio F, Ierardi E.
    Neurogastroenterol Motil; 2012 Sep; 24(9):836-e396. PubMed ID: 22680042
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.
    Inflamm Bowel Dis; 2013 Sep; 19(4):761-6. PubMed ID: 23446337
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, Ponsioen C, van Tuyl BA, Siersema PD, Fidder HH, Oldenburg B, Dutch Initiative on Crohn and Colitis (ICC).
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [Abstract] [Full Text] [Related]

  • 13. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S.
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [Abstract] [Full Text] [Related]

  • 14. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B, Zingone F, D'Incà R, Rovigo L, Bertani L, Bodini G, Ghisa M, Gubbiotti A, Massimi D, Lorenzon G, Savarino EV.
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [Abstract] [Full Text] [Related]

  • 15. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
    Schaeffer DF, Walsh JC, Kirsch R, Waterman M, Silverberg MS, Riddell RH.
    Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [Abstract] [Full Text] [Related]

  • 19. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
    Patil SA, Rustgi A, Langenberg P, Cross RK.
    Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.